<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://gate.unigre.it/mediawiki/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=ReinaldoTew087</id>
	<title>GATE - User contributions [en]</title>
	<link rel="self" type="application/atom+xml" href="https://gate.unigre.it/mediawiki/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=ReinaldoTew087"/>
	<link rel="alternate" type="text/html" href="https://gate.unigre.it/mediawiki/index.php/Special:Contributions/ReinaldoTew087"/>
	<updated>2026-05-30T13:19:49Z</updated>
	<subtitle>User contributions</subtitle>
	<generator>MediaWiki 1.35.7</generator>
	<entry>
		<id>https://gate.unigre.it/mediawiki/index.php?title=Substance_Details_ADB-BUTINACA&amp;diff=148799</id>
		<title>Substance Details ADB-BUTINACA</title>
		<link rel="alternate" type="text/html" href="https://gate.unigre.it/mediawiki/index.php?title=Substance_Details_ADB-BUTINACA&amp;diff=148799"/>
		<updated>2026-05-27T06:54:56Z</updated>

		<summary type="html">&lt;p&gt;ReinaldoTew087: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;The current study indicates that the test compounds produce locomotor depression similar to that of Δ9-THC, and fully substitute for the discriminative stimulus effects of Δ9-THC. In summary, these 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA have similar abuse liability as Δ9-tetrahydrocannabinol and should be controlled in a similar fashion. Much of the in vivo [https://cannabinoidsrc4f-adb.com/ 5CLADBA] testing of the synthetic cannabinoid compounds have been pre-clinical studies focused on their cannabinoid-like effects or like the present study, focused on their abuse liability. There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Figure 1. &amp;lt;br&amp;gt;These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;In-vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16&amp;lt;br&amp;gt;&amp;lt;br&amp;gt; Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans &amp;lt;br&amp;gt;The % peak area abundance ratio of metabolites detected in the urine samples are often affected by numerous factors such as drug intake behaviour (intake route, amount of drug and intake frequency), time from last drug intake and metabolic stability. This indicated that the phase I metabolism of 4F-MDMB-BINACA are unlikely to be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation (B17) metabolite, the second major metabolite after monohydroxylation in the C. Ester hydrolysis with dehydrogenation formed in-vivo in this study was also reported among other indazole carboxamide type SCBs with tert-leucine methyl ester moieties such as 5F-MDMB-PINACA and MDMB-4en-PINACA [39, 40]. Similar to the in-vivo findings, 4F-MDMB-BINACA ester hydrolysis (B22) was the major metabolite for both HepG2 and HLM models, consistent with the known hydrolytic activity of CES reported&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;§ (3) of the Hungarian act of Forensic Experts (2016.XXIX), the data of the reported case can be utilized freely for scientific and educational purposes without special ethical permission. These results indicate that the simultaneous intoxication of SCRA and ethanol directly and exclusively caused the death of the two victims. The victims did not have any significant diseases that could have contributed to the outcome. Very limited data are available in the scientific literature about the possible effects of the combined consumption of SCRAs and ethanol. Several case reports describe that the presence of a little ng/mL (0.37–4.1) of SCRAs and a high—but not lethal—concentration of ethanol (1.45–2.7 g/L) directly and exclusively contributed to the death of the victim [24–27] (Table 2). The fact that 4F-MDMB-BINACA was not detected in postmortem urine samples is partly explained by the high rate of hepatic metabolism of SCRAs [11, 14, 22], but also suggests that the victims consumed 4F-MDMB-BINACA shortly before their death&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Figure 1. &amp;lt;br&amp;gt;Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin&lt;/div&gt;</summary>
		<author><name>ReinaldoTew087</name></author>
	</entry>
</feed>